Australia's Prescient Therapeutics soars on EU orphan drug tag for cancer therapy
19/11/2025 24:41
** Shares of Prescient Therapeutics PTX.AX rise as much as 29.2% to A$0.062, their highest level since December 23, 2024 ** Clinical-stage oncology company heading for best day since December 2024, if gains hold ** Co says European Medicines Agency grants orphan drug designation to PTX-100 for treating cutaneous T-cell lymphoma ** About 4.4 million shares change hand, 3.9x 30-day average ** Stock up 10% this year, including the day's move (Reporting by John Biju in Bengaluru) ((John.Biju@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial